140 related articles for article (PubMed ID: 38083430)
1. Automatic Visual Acuity Loss Prediction in Children with Optic Pathway Gliomas using Magnetic Resonance Imaging.
Jiang Z; Parida A; Anwar SM; Tang Y; Roth HR; Fisher MJ; Packer RJ; Avery RA; Linguraru MG
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083430
[TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
3. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
4. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
5. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
6. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.
Avery RA; Mansoor A; Idrees R; Trimboli-Heidler C; Ishikawa H; Packer RJ; Linguraru MG
Neurology; 2016 Dec; 87(23):2403-2407. PubMed ID: 27815398
[TBL] [Abstract][Full Text] [Related]
7. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
8. Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
Kilian A; Aigner A; Simon M; Salchow DJ; Potratz C; Thomale UW; Hernáiz Driever P; Tietze A
J Neurooncol; 2022 Feb; 156(3):589-597. PubMed ID: 34994964
[TBL] [Abstract][Full Text] [Related]
9. Vision specific quality of life in children with optic pathway gliomas.
Avery RA; Hardy KK
J Neurooncol; 2014 Jan; 116(2):341-7. PubMed ID: 24197987
[TBL] [Abstract][Full Text] [Related]
10. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
13. Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?
Aquilina K; Daniels DJ; Spoudeas H; Phipps K; Gan HW; Boop FA
Childs Nerv Syst; 2015 Nov; 31(11):2041-9. PubMed ID: 26277358
[TBL] [Abstract][Full Text] [Related]
14. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.
Rony C; Aharoni S; Halevy A
Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604
[TBL] [Abstract][Full Text] [Related]
15. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
16. Measurements of Retinal Nerve Fiber Thickness and Ganglion Cell Complex in Neurofibromatosis Type 1, with and Without Optic Pathway Gliomas: A Case Series.
Sahinoglu-Keskek N; Altan-Yaycioglu R; Canan H; Coban-Karatas M; Erbay A; Yazıcı N; Alkan O
Curr Eye Res; 2018 Mar; 43(3):424-427. PubMed ID: 29185816
[TBL] [Abstract][Full Text] [Related]
17. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
Wan MJ; Ullrich NJ; Manley PE; Kieran MW; Goumnerova LC; Heidary G
J Neurooncol; 2016 Aug; 129(1):173-8. PubMed ID: 27311725
[TBL] [Abstract][Full Text] [Related]
18. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
19. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]